Clinical Trial Update: A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating enzalutamide in combination with AZD5363 for metastatic castration-resistant prostate cancer (mCRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• AZD5363 (capivasertib)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: UNKNOWN